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ABSTRACT
High-throughput screening of a National Cancer
Institutelibraryofpurenaturalproductsidentifiedthe




6-one) as potent and selective inhibitors of the
ribonuclease H (RNase H) activity of human immun-
odeficiency virus-type 1 reverse transcriptase (HIV-1
RT). b-Thujaplicinol inhibited HIV-1 RNase H in vitro
with an IC50 of 0.2 mM, while the IC50 for Escherichia
coli and human RNases H was 50 mM and 5.7 mM,
respectively. In contrast, the related tropolone
analog b-thujaplicin (2-hydroxy-4-(methylethyl)-2,4,
6-cycloheptatrien-1-one), which lacks the 7-OH
groupoftheheptatrienering,wasinactive,whileman-
icol, which possesses a 7-OH group, inhibited HIV-1
and E.coli RNases H with IC50 = 1.5 mM and 40 mM,
respectively. Such a result highlights the importance
of the 2,7-dihydroxy function of these tropolone ana-
logs, possibly through a role in metal chelation at the
RNaseHactivesite. Inhibition ofHIV-2RT-associated
RNaseHindirectlyindicatesthatthesecompoundsdo
not occupy the nonnucleoside inhibitor-binding
pocket in the vicinity of the DNA polymerase domain.
Bothb-thujaplicinolandmanicolfailedtoinhibitDNA-
dependent DNA polymerase activity of HIV-1 RT at a
concentration of 50 mM, suggesting that they are
specificfortheC-terminalRNaseHdomain,whilesur-
face plasmon resonance studies indicated that the
inhibition was not due to intercalation of the analog
into the nucleic acid substrate. Finally, we have
demonstrated synergy between b-thujaplicinol and
calanolide A, a nonnucleoside inhibitor of HIV-1 RT,
raisingthepossibilitythatbothenzymaticactivitiesof
HIV-1 RT can be simultaneously targeted.
INTRODUCTION
Reverse transcriptase (RT)-associated ribonuclease H
(RNase H) activity is responsible for both non-speciﬁcally
degrading the RNA strand of the RNA/DNA replication inter-
mediate as well as speciﬁcally removing the minus ( ) and
plus (+) strand RNA primers [tRNA and the polypurine tract
(PPT), respectively] from nascent DNA (1). The absolute
requirement for RNase H activity for human immunodeﬁ-
ciency virus (HIV) replication (2,3) suggests that this might
be an attractive target for the development of antiviral agents
to complement DNA polymerase-based HIV-1 RT inhibitors
currently in clinical use [reviewed in (4)]. In this respect,
recent reports have documented several promising candidates
effective at low micromolar concentrations, including
hydrazones (5–7), tetragalloylglucopyranose (8), diketo
acids (9) and N-hydroxyimides (10). Although it remains to
be established that their mode of inhibition is through direct
binding to the RNase H catalytic center, both diketo acids
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doi:10.1093/nar/gki268and N-hydroxyimides have been shown to inhibit an enzymat-
ically active peptide derived from the RNase H domain of
HIV-1 RT (9,11). Thus, while antiviral activity of these select
RNase H antagonists is yet to be demonstrated, sufﬁcient
evidence has accumulated to justify further screening for
inhibitors of HIV-1 and HIV-2 RNase H. Moreover, although
Klumpp et al. (10) have recently evaluated N-hydroxyimides
for the inhibition of retroviral and bacterial RNases H, none of
the more potent HIV-1 RNase H inhibitors reported to date has
addressed selectivity with respect to the human counterpart.
This issue is of particular importance, since recent data have
indicated that disruption of the RNase H1 allele in mice
confers a lethal embryonic defect (12). To take this issue
into account, we recently described two simple, robust
ﬂuorescence-based methodologies which could be applied in
parallel to retroviral, bacterial and human RNases H using
the same assay platform, together with their use for high-
throughput screening (13,14). The availability of puriﬁed
human RNase H1 has also allowed us to investigate the speci-
ﬁcityofinhibitorsuncoveredfromourcurrentscreeningefforts.
Here, we describe two tropolone (2-hydroxy-2,4,6-
cycloheptatrien-1-one) derivatives with a 7-OH substitution,
identiﬁed from high-throughput screening of National Cancer
Institute libraries of pure natural products, which inhibit ret-
roviral, bacterial and human RNases H. Inhibition of HIV-2
RNase H activity indirectly indicates that these compounds do
not interact with the nonnucleoside-binding site located near
the DNA polymerase catalytic centerof this enzyme. The most
potent of the hydroxylated tropolone analogs, b-thujaplicinol,
derived from the heartwood of several cupressaceous plants
(e.g. Thuja plicata, Thuja occidentalis and Chamaecyparis
obtusaI) (15–17), is active at sub-micromolar concentrations
against the RNases H of HIV-1 and HIV-2 RT, while the DNA
polymerase activity of either enzyme is unaffected at an inhib-
itor concentration of 50 mM. The same compound is  30- to
250-fold less active against the human and Escherichia coli
RNases H, respectively, demonstrating that selective inhibi-
tion of the retroviral enzyme can be achieved. Finally, we
demonstrate here that b-thujaplicinol acts synergistically
with calanolide A, a nonnucleoside inhibitor of HIV-1 RT
(18,19), opening the possibility of simultaneously targeting
the DNA polymerase and RNase H functions of HIV-1 and
HIV-2 RT.
A number of reports have demonstrated that tropolone
derivatives elicit a variety of biological effects, including
anti-tumor (20), insecticidal (21), antifungal (22,23) and anti-
microbial (24) activity, while their metal chelates have been
shown to inhibit human inﬂuenza virus-induced apoptosis
(25). Wakabayashi et al. (26) have investigated cytotoxic
activity of tropolone derivatives against a variety of human
oral tumor cell lines, and also indicated that they fail to protect
MT-4 cells from HIV-1 infection.
MATERIALS AND METHODS
Tropolone derivatives








methylethyl)-2,4,6-cycloheptatrien-1-one] are provided in
Figure 1. All compounds were members of a National Cancer
Institute library of puriﬁed, natural compounds, and their iden-
tity and purity were conﬁrmed by
1H-NMR. Each compound
was prepared as a 20 mM stock solution in 100% dimethyl
sulfoxide (DMSO) and diluted into the appropriate reaction
buffer immediately prior to analysis.
Enzymes and enzyme assays
Recombinant, wild-type p66/p51 HIV-1 RT was expressed
and puriﬁed as described previously (27). HIV-2 RT was pre-
pared using the same E.coli expression system (27). E.coli
RNase HI and recombinant human RNase H were prepared
as described previously (28,29). The strategy for high-
throughput screening and conﬁrmation of RNase H activity
by capillary electrophoresis has recently been described by
Parniak et al. (13) and Chan et al. (14), respectively. For
HIV-1 RT, conditions for cleavage of the HIV-1 PPT RNA
primer extended at its 30 terminus by ﬁve deoxynucleotides
have been described by Kvaratskhelia et al. (30). DNA-
dependent DNA polymerase activity was analyzed on a 71 nt
DNA to which a [
32P]labeled 36 nt DNA primer was hybrid-
ized as described by Dash et al. (31). For qualitative analysis
of PPT cleavage and DNA-dependent DNA polymerase
activity, all tropolone derivatives were evaluated at a single
concentration of 50 mM.
Surface plasmon resonance analysis
All experiments were performed with a Biacore 2000 optical
biosensor at 25 C. CM5 Sensor chips with a carboxymethyl-
ated dextran matrix, EDC, NHS and P20 surfactant were
obtained from Biacore AB, (Uppsala, Sweden), and strepta-
vidin was from Pierce (Rockford, IL). Streptavidin was
immobilized on the sensor chip surface to the level of  4000–
4500 RU in each ﬂow cell. Biotinylated nucleic acid (12mer
RNA–DNA hybrid in the form of a hairpin within which a
thymidine residue of a connection tetraloop was biotinylated)
was injected at a concentration of 50 nM in HBS buffer
(10 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.005%
P20, pH 7.4) onto streptavidin-modiﬁed chip surface at a ﬂow
rate of 5 ml/min until the desired level ( 1000–1500 RU) of
immobilization was achieved. Blocking of unoccupied strep-
tavidin with biotin and washing the chip with regeneration
buffer (2 M NaCl) was performed as described previously
(28). Experiments on inhibitor or marker binding to nucleic
acid were carried out in Tris-buffered saline/DMSO running
buffer (10 mM Tris–HCl, 50 mM NaCl, 1 mM EDTA, 0.005%
P20, 5% DMSO, pH 8.0) using a ﬂow rate of 50 ml/min.
Typically, 50 ml of a marker or inhibitor (each separately or
in mixtures of2or 3simultaneously) dilutedinthe samebuffer
intheconcentration range of50 nMto10mMwassuccessively
injected using the ‘kinject’ command deﬁning a dissociation
time of 2 min. After each round of injection, the system was
intensivelywashedusingrunningbuffer.Allexperimentswere
performed in duplicate. Data transformation of the primary
sensograms and overlay plots were prepared using the
1250 Nucleic Acids Research, 2005, Vol. 33, No. 4BIAevaluation 3.0 software (Biacore AB). The response from
the reference ﬂow cell that does not contain nucleic acid was
subtracted from that of the experimental ﬂow cell.
IC50 and Ki determinations
Dose–response plots were prepared by measuring RNase H
activity on a ﬂuorescent RNA/DNA hybrid as described pre-
viously (13) while varying the inhibitor concentration by 2-
fold dilutions from 100 mM to 0.19 nM. Curve ﬁtting was
performed using Sigma Plot. In order to determine the Ki
for b-thujaplicinol, the substrate concentration was varied
from 200 to 1.56 nM while varying the inhibitor concentration
from 1.56 to 0.024 nM at each substrate concentration.
Hydrolysis was followed by ﬂuorescence measurements at
40 s intervals over the 30 min reaction time using a Molecular
Devices Spectramax Gemini EM ﬂuorescence spectrometer.
Slopes of the reaction curves were determined from the linear
portion of the plots using SoftMAX Pro version 4.3 supplied
with the instrument. Curve ﬁtting and prediction of the mode
of inhibition was performed using the Enzyme Kinetics mod-
ule of Sigma Plot version 8 (SPSS, Chicago, IL).
Synergy between RNase H and DNA polymerase
inhibitors
In order to determine whether the binding site for b-thujapli-
cinol overlapped that of nonnucleoside RT inhibitors, RNase
H activity was measured in the presence of varying concen-
trations of tropolone inhibitor and varying concentrations of
the nonnucleoside calanolide A (18) according to the method
of Yonetani and Theorell (32) and Cook et al. (33). Data were
processed using the Calcusyn software package (BioSoft,
Cambridge, UK).
RESULTS
Tropolone derivatives specifically inhibit HIV-1
RNase H function
The structures of the tropolone derivatives used in the present
study are provided in Figure 1. Since HIV-1 RT is a bifunc-
tional enzyme, inhibition of RNase H activity might reﬂect
direct binding to the RNase H domain or, alternatively, an
allosteric effect through binding to the nonnucleoside-
binding pocket close to the DNA polymerase domain,
which has been shown previously to modulate RNase H func-
tion (34). Preliminary experiments were, therefore, designed
to investigate the speciﬁcity of each analog for the RNase H
activity of HIV-1 RT. In Figure 2A, RNase H activity was
evaluated on a 50[
32P]labeled RNA–DNA chimera hybridized
toits DNA complement,whichmimics processingofthe HIV-1
PPT primer from nascent DNA, following initiation of second
or (+) strand synthesis. Using this substrate, we have previously
demonstrated RNase H cleavage at the PPT RNA-U3 DNA
junction (deﬁned as  1), and additionally at positions  2
and  3 (30). For these initial experiments, a single analog
concentration of 50 mM was employed, which resulted
in almost complete inhibition of PPT processing by both
Figure 1. Structures of tropolone and its derivatives.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1251b-thujaplicinol (lane 4) and manicol (lane 7). In Figure 2B, the
same derivatives were re-evaluated for their ability to inhibit
DNA-dependentDNApolymeraseactivityona duplexcontain-
ing a 50[32P]labeled 36 nt DNA primer hybridized to a 71 nt
DNA template. At a single concentration of 50 mM, negligible
inhibition of DNA polymerase activity was observed for all
analogs. The combined data of Figure 2 thus indicate that
inhibition of HIV-1 RNase H activity is not an consequence
of analog binding to the DNA polymerase catalytic center and
exerting an indirect effect, as has been reported for certain
diketo acids and phenylhydrazones by Shaw-Reid et al.( 9 ) .
Selectivity of inhibition
Clearly, a desirable feature of an inhibitor of retroviral RT-
associated RNase H activity would be selectivity with respect
to its human counterpart. To address this issue, b-thujaplicinol
and manicol were examined for their inhibitory effect on the
RTsofHIV-1andHIV-2aswellashumanRNaseH.Figure3A
indicates that b-thujaplicinol inhibited HIV-1 RT with an IC50
of 0.21 – 0.03 mM. For HIV-2 RT, the IC50 for the same analog
was  3-fold higher (Figure 3C, 0.77 – 0.08 mM). Such a result
might reﬂect subtle differences in the architecture of RNase H
domainsofthesetwoenzymes,whichhasbeensuggestedfrom
biochemical analysis of the puriﬁed RTs (35). More import-
antly, b-thujaplicinol inhibited human RNase H with an IC50
of 5.7 – 0.7 mM (Figure 3E), indicating  30-fold selectivity
forthe HIV-1enzyme.Althoughnotshownhere,anIC50 value
of 50 mM was determined for E.coli RNase H, indicating that
this enzyme was  250-fold less sensitive to b-thujaplicinol
inhibition. In Figure 3B, D and F, inhibition of retroviral and
human RNases Hbymanicolwas compared. While this analog
was slightly less potent against HIV-1 RNase H (IC50 =
0.60 – 0.09 mM), 6-fold enhanced selectivity over the
human enzyme was achieved (IC50 = 3.5 – 0.1 mM).
IC50 values for tropolone and its derivatives are presented
in Table 1. Interestingly, b-thujaplicin, which differs from
b-thujaplicinol in that it lacks the hydroxyl function at position
7 of the heptatriene ring, was completely inactive against all
enzymes tested, despite reports that it possesses metal chelat-
ing properties (36). Relocation of the hydroxyl function on
the heptatriene ring produced a different effect, i.e. while g-
thujaplicin failed to inhibit retroviral RNases H, a-thujaplicin
was weakly active, with an IC50 value of 50 and 33 mM for
the HIV-1 and HIV-2 enzymes, respectively.
b-Thujaplicinol does not inhibit RNase H activity
through intercalation
Although DNA polymerase activity was unaffected, one pos-
sible mode of inhibition we had to consider was the intercala-
tion of the planar tropolone derivatives into the RNA/DNA
A
B
Figure 2. (A) Inhibition of HIV-1 RT-catalyzed polypurine tract processing by tropolone and its derivatives. Left, schematic representation of the RNase H assay.
Right,RNaseHactivityinthepresenceof50mMtropolonederivative.LaneC,noinhibitor;lane1,noinhibitor,+DMSO;lane2,b-thujaplicin;lane3,a-thujaplicin;
lane 4, b-thujaplicininol; lane 5, g-thujaplicin; lane 6, nootkatin; lane 7, manicol; and lane 8, tropolone. PPT hydrolysis products have been indicated. (B) DNA-
dependent DNA polymerase activity of HIV-1 RT in the presence of tropolone and hydroxylated derivatives. DNA polymerase activity was determined at a single
inhibitor concentration of 50 mM. Lane notations are as in (A).
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enzyme binding. In order toeliminate this possibility, inhibitor
binding to an immobilized RNA/DNA hybridwas investigated
via surface plasmon resonance, which we have successfully
used to investigate the binding properties of HIV-1 RT deriv-
atives (37). As a control, binding of ethidium bromide to the
immobilized hybrid was analyzed, the results of which are
depicted in the sensorgram of Figure 4A. From this data,
we calculated that 4–6 molecules of ethidium bromide inter-
calated into the hybrid with a Kd of  1.5 mM. In contrast, data
of Figure 4B, which presents the combined sensorgrams
obtained when the RNA/DNA hybrid was incubated with
a-thujaplicin, b-thujaplicin and b-thujaplicinol, clearly indic-
ate that they do not bind the substrate over a concentration
range of 50 nM–10 mM.
Mode of inhibition
b-Thujaplicin and manicol were further investigated in order
to gain insight into their mechanism of inhibition of HIV-1
Figure 3. Selectivity of RNase H inhibition. Dose–response curves for RNase I inhibition by b-thujaplicinol (A, C and E) and manicol (B, D and F) are presented.
(A and B) HIV-1 RT; (C and D), HIV-2 RT; (E and F), human RNase H. IC50 determinations are the results of triplicate assays.
Table 1. Inhibition of retroviral, bacterial and human RNases H by hydroxylated tropolone derivatives
Compound IC50 HIV-1 RT (mM) IC50 HIV-2 RT (mM) IC50 E.c. Rnase H (mM) IC50 Hu Rnase H (mM)
Tropolone >100 >100 >100 3.0
b-Thujaplicin >100 >100 >100 >100
g-Thujaplicin >100 >100 >100 2.0
Nootkatin >100 >100 >100 25
a-Thujaplicin 50 33 >100 12
Manicol 60 1.7 40 3.5
b-Thujaplicinol 0.21 0.77 50 5.7
IC50 values are the average of triplicate analyses.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1253RT/RNase H. From the Michaelis–Menten plot of Figure 5, a
Ki of 0.20 – 0.07 mM was determined for b-thujaplicinol, and a
separate study indicated a Ki of 1.0 – 0.4 mM for manicol (data
not shown). The data presented in Figure 5 show a change in
Vmax without affecting the Km, which is suggestive of mixed
inhibition. Non-linear ﬁtting of the data conﬁrms that this is
best ﬁt to mixed-type inhibition compared with competitive or
uncompetitive modes. With this type of inhibition, the antag-
onist can bind either the free enzyme or the enzyme–substrate
complex. This suggests that the tropolone derivatives could
occupy (or create) a pocket near the RNase H active site, since
access to that site would be impaired by the RNA/DNA duplex
substrate.
b-Thujaplicinol and the nonnucleoside calanolide
A occupy different sites on HIV-1 RT
The multifunctional nature of HIV-1 RT opens the possibility
that antiviral agents could be separately targeted to the DNA
polymerase and RNase H catalytic centers. In order to assess
this, we investigated whether b-thujaplicinol would act in
combination with calanolide A (18). This coumarin derivative,
isolated from the tropical rainforest tree Calophyllum
lanigerum, has been shown to inhibit HIV-1 RT activity by
a mechanism similar to other nonnucleoside-based drugs (19).
Figure 6 presents a Yonetani–Theorell plot of RNase
H inhibition in the presence of both calanolide A and
b-thujaplicinol. The data indicate that the inhibitors bind to
two independent sites since the plot shows converging lines
(32). In addition, HIV-2 is naturally resistant to NNRTIs; thus,
inhibition of HIV-2 RNase H is additional, albeit indirect,
evidence that b-thujaplicinol binds to an independent site.
Independent binding sites for calanolide A and b-thujaplicinol
were further supported by inhibitor-combination assays using
the methods described by Chou and Talalay (38,39). The com-
bination index (CI) derived for mixed inhibitors can be used to
describe additivity (CI = 1), synergy (CI < 1) and antagonism
(CI > 1). The inhibitor combination of b-thujaplicinol/
calanolide A was found to be 0.50, i.e. the inhibition by a
b-thujaplicinol/calanolide A combination is more potent than
predicted by adding the effect of the individual inhibitors. This
synergistic effect would not be observed with inhibitors com-
peting for the same or closely positioned binding sites. In a
control experiment, a CI of 1.8 was determined for a b-thu-
japlicinol/manicol combination, indicating antagonism. This
would be predicted, since the two tropolone derivatives most
likely compete for the same binding site.
DISCUSSION
In this communication, we demonstrate that the natural pro-
ducts b-thujaplicinol and manicol, derived from the heartwood
of several cupressaceous trees, inhibit the RNase H activity of
HIV-1 and HIV-2 RT at sub-micromolar concentrations with-
out affecting DNA polymerase function of either enzyme.
Moreover, the most potent inhibitor, b-thujaplicinol, is  30-
fold more active on HIV-1 RT/RNase H than on human RNase
Figure 5. Michaelis–Menten plot for the determination of the Ki for b-thuja-
plicinol for HIV-1 RT-associated RNase H. A Ki of 0.20 – 0.07 mM was
determined from non-linear curve fitting. Inhibitor concentrations were
0.024 mM (open circle), 0.049 mM (filled triangle), 0.098 mM (open triangle),
0.20 mM (filled square), 0.39 mM (open square), 0.78 mM (filled diamond),




Figure 4. Analysis of inhibitor intercalation by surface plasmon resonance. In
(A), binding of ethidium bromide to an immobilized 12mer RNA/DNA hybrid
was performed as a control. Sensorgrams a–f illustrate the response to succes-
siveinjectionoftheintercalatoratconcentrationsof10,5,1.0,0.5,0.25and0.1
mM, respectively. (B) Combined sensorgrams following injection of b-thuja-
plicin, a-thujaplicin and b-thujaplicinol over the same concentration range
as in (A).
1254 Nucleic Acids Research, 2005, Vol. 33, No. 4H1. In light of the requirement for RNase H1 during embry-
onal development in mice (12), selectivity of the retroviral
enzyme over the human counterpart should be a major goal
during antiviral drug development, but to date had not been
addressed. Finally, our data indicate that b-thujaplicinol and
the nonnucleoside inhibitor calanolide A (18,19) occupy dif-
ferent sites on HIV-1 RT, raising the possibility that the DNA
polymerase and RNase H domains of HIV-1 RT might be
simultaneously targeted by antiviral agents.
Although the mechanistic basis for retroviral RNase H
inhibition observed here remains to be established, the data
of Figure 1 and Table 1 provide some insights. Since the
b-diketone moiety of thujaplicins has been demonstrated cap-
able of chelating metals, such as Cu
++ and Zn
++ (36), chelating
and/or altering the co-ordination geometry of the divalent
metal in the RNase H catalytic center essential for catalysis
would seem a plausible mechanism of action. However, we
observe here that neither b-thujaplicin nor g-thujaplicin is
active against the retroviral enzymes, while a-thujaplicin is
only modestly active (Table 1). b-thujaplicinol introduces a
second hydroxyl function at position 7 of the heptatriene
ring, which substantially improves potency. At the same
time, although manicol introduces a bulky substituent onto
the heptatriene ring, it provides almost the same potency
against HIV-1 RNase H as b-thujaplicinol. While addition
of the 7-OH function enhances the speciﬁcity for HIV-1
and HIV-2 RT/RNase H, it has little to no effect on potency
against the bacterial and human enzymes. Poor inhibition of
E.coli RNase H and the consistent but modest inhibition of
human RNase H by all tropolones tested suggests that if metal
chelation is responsible for inhibition, the 7-OH function is
critical for stabilizing an interaction, which is speciﬁc to the
active-site geometry of the retroviral enzymes. Interestingly, a
two-metal catalyzed catalytic mechanism has been proposed
for HIV-1 RNase H, based on crystallographic data with the
isolated Mn
++-doped domain showing two divalent cations at
the active site (40). Although speculative, the potency we
observe for b-thujaplicinol may reﬂect its ability to form a
more stable complex with the divalent cation at both metal-
binding sites. If an interaction with the divalent cation at
the RNase H catalytic center is the basis for inhibition by
b-thujaplicinol and manicol, it is interesting to note that
these two compounds do not inhibit DNA polymerase func-
tion, despite the fact that the equivalent divalent cation is
coordinated in this catalytic center by a triad of carboxyate
residues (Asp110, Asp185 and Asp186). One possible
explanation might be that the divalent cation is more tightly
bound at the DNA polymerase catalytic center and thus more
difﬁcult to access. However, titration calorimetry studies sug-
gest the contrary, namely that the divalent cation in the RNase
H catalytic center is more tightly coordinated (41). Based on
these observations, differences in the overall architecture of
the metal-binding site might exclude these inhibitors from the
polymerase catalytic center. Further studies of the interaction
ofb-thujaplicinol andmanicolwith HIV-1andHIV-2RThave
the potential to clarify their mechanism of action. While inact-
ive in cellular models of HIV-1 infection, these two com-
pounds nonetheless will serve as useful probes of HIV-1
and HIV-2 RNase H enzymology. For example, recent studies
have suggested that inhibition of HIV-1 RNase H activity
might increase the rate at which chain terminators of DNA
synthesis are excised, thus leading to enhanced nucleoside
resistance (V. Pathak, personal communication). The availab-
ility of inhibitors selective for the RNase H activity of HIV-1
RT will allow this hypothesis to be directly evaluated in vitro.
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